Raymond James expects AMAG Pharmaceuticals shares to rebound sharply once the McGuff's labeled indication becomes more widely known. The firm just received a response letter to its FOIA request for the McGuff hydroxyprogesterone caproate (17P) label and said it appears the FDA has taken a much more restrictive approach than many anticipated. Raymond James does not see how McGuff could possible pose a threat to AMAG's Makenas and said its estimates are safe and recommends buying shares aggressively. Raymond James rates AMAG Pharmaceuticals an Outperform.